DK2276541T3 - Opretholdelse af trombocythæmning under antitrombocytbehandling - Google Patents
Opretholdelse af trombocythæmning under antitrombocytbehandling Download PDFInfo
- Publication number
- DK2276541T3 DK2276541T3 DK09747490.2T DK09747490T DK2276541T3 DK 2276541 T3 DK2276541 T3 DK 2276541T3 DK 09747490 T DK09747490 T DK 09747490T DK 2276541 T3 DK2276541 T3 DK 2276541T3
- Authority
- DK
- Denmark
- Prior art keywords
- reversible
- short
- acting
- inhibitor
- platelet
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title claims description 47
- 238000011282 treatment Methods 0.000 title description 21
- 238000000034 method Methods 0.000 claims description 68
- 230000002441 reversible effect Effects 0.000 claims description 64
- 239000003112 inhibitor Substances 0.000 claims description 51
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 39
- PAEBIVWUMLRPSK-IDTAVKCVSA-N cangrelor Chemical group C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O PAEBIVWUMLRPSK-IDTAVKCVSA-N 0.000 claims description 39
- 229960001080 cangrelor Drugs 0.000 claims description 39
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 39
- 238000001802 infusion Methods 0.000 claims description 38
- 229960003009 clopidogrel Drugs 0.000 claims description 35
- 229940125670 thienopyridine Drugs 0.000 claims description 30
- 239000002175 thienopyridine Substances 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 24
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 claims description 15
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 10
- 239000002172 P2Y12 inhibitor Substances 0.000 claims description 9
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 210000004351 coronary vessel Anatomy 0.000 claims description 4
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 claims description 3
- 108050008996 P2Y purinoceptor 1 Proteins 0.000 claims description 3
- 210000001772 blood platelet Anatomy 0.000 description 61
- 238000001356 surgical procedure Methods 0.000 description 44
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 20
- 208000032843 Hemorrhage Diseases 0.000 description 20
- 229960001138 acetylsalicylic acid Drugs 0.000 description 20
- 208000034158 bleeding Diseases 0.000 description 17
- 231100000319 bleeding Toxicity 0.000 description 17
- 230000000740 bleeding effect Effects 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 238000013176 antiplatelet therapy Methods 0.000 description 13
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 12
- 230000000302 ischemic effect Effects 0.000 description 12
- 208000007536 Thrombosis Diseases 0.000 description 11
- 238000011977 dual antiplatelet therapy Methods 0.000 description 9
- 230000010118 platelet activation Effects 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 7
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 230000002427 irreversible effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002980 postoperative effect Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000000702 anti-platelet effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 206010000891 acute myocardial infarction Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 229940020573 plavix Drugs 0.000 description 4
- 206010002388 Angina unstable Diseases 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 238000009115 maintenance therapy Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010071229 Procedural haemorrhage Diseases 0.000 description 2
- 208000007718 Stable Angina Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- -1 clopidogrel Chemical compound 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000013171 endarterectomy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 102000008212 P-Selectin Human genes 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000007892 surgical revascularization Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
Claims (14)
1. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde til mindst delvis hæmning af trombocytaktiviteter hos en person, der tidligere er behandlet med mindst én thienopyridin, hvor behandling med den mindst ene thienopyridin afbrydes før administrering af den reversible, korttidsvirkende P2Yi2-hæmmer, hvor den reversible, korttidsvirkende P2Yi2-hæmmer er cangrelor og administreres til personen op til 5 dage før, der skal udføres en invasiv procedure på personen, eller mens en invasiv procedure udføres på personen.
2. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge krav 1, hvor den hæmmende aktivitet af den mindst ene thienopyridin er ikke-reversibel.
3. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge krav 1 eller krav 2, hvor den mindst ene thienopyridin er clopidogrel.
4. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor administration af den mindst ene thienopyridin til personen afbrydes mindst 5 dage før, der skal udføres en invasiv procedure på personen.
5. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor fremgangsmåden omfatter administration af den reversible, korttidsvirkende P2Yi2-hæmmer til personen op til 5 dage før, der skal udføres en invasiv procedure på personen.
6. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge krav 1, hvor administration of cangrelor afbrydes mellem 1 og 24 timer før den invasive procedure.
7. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge krav 1, hvor cangrelor administreres som en intravenøs infusion af mellem 0,5 og 2,0 yg/kg/minut.
8. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge et hvilket som helst af kravene 4 til 7, hvor den invasive procedure er en koronararterie-bypassoperation.
9. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge et hvilket som helst af kravene 4 til 7, hvor den invasive procedure er et perkutant koronarindgreb.
10. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, hvor personen tidligere har fået indsat en stent.
11. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge krav 10, hvor stenten er en "nøgen" metalstent.
12. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge krav 10, hvor stenten er en lægemiddel-eluerende stent.
13. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor hæmningen af trombocytaktivitet er en hæmning på mere end ca. 60 %.
14. Reversibel, korttidsvirkende P2Yi2-hæmmer til anvendelse i en fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor trombocytaktiviteten er trombocytaggregering.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12741408P | 2008-05-13 | 2008-05-13 | |
| PCT/US2009/043820 WO2009140407A1 (en) | 2008-05-13 | 2009-05-13 | Maintenance of platelet inhibition during antiplatelet therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2276541T3 true DK2276541T3 (da) | 2016-11-28 |
Family
ID=41319000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09747490.2T DK2276541T3 (da) | 2008-05-13 | 2009-05-13 | Opretholdelse af trombocythæmning under antitrombocytbehandling |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8871736B2 (da) |
| EP (1) | EP2276541B1 (da) |
| JP (2) | JP5792059B2 (da) |
| CN (1) | CN102089035A (da) |
| AU (1) | AU2009246396B2 (da) |
| BR (1) | BRPI0912693B8 (da) |
| CA (1) | CA2724470C (da) |
| CY (1) | CY1118653T1 (da) |
| DK (1) | DK2276541T3 (da) |
| ES (1) | ES2601524T3 (da) |
| HR (1) | HRP20161443T1 (da) |
| HU (1) | HUE031704T2 (da) |
| LT (1) | LT2276541T (da) |
| PL (1) | PL2276541T3 (da) |
| PT (1) | PT2276541T (da) |
| SI (1) | SI2276541T1 (da) |
| WO (2) | WO2009140092A1 (da) |
Families Citing this family (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759316B2 (en) | 2008-05-13 | 2014-06-24 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US8680052B1 (en) * | 2013-03-09 | 2014-03-25 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| WO2009140092A1 (en) | 2008-05-13 | 2009-11-19 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US9427448B2 (en) | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US20120141468A1 (en) * | 2008-05-13 | 2012-06-07 | Lisa Ruderman Chen | Maintenance of platelet inhibition during antiplatelet therapy |
| US20130303477A1 (en) | 2008-05-13 | 2013-11-14 | The Medicines Company | Maintenance of Platelet Inhibition During Antiplatelet Therapy |
| BR112012011298B1 (pt) * | 2009-11-11 | 2021-12-14 | Chiesi Farmaceutici S.P.A. | Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| JP5947316B2 (ja) * | 2011-02-09 | 2016-07-06 | ザ メディシンズ カンパニー | 肺高血圧症を処置するための方法 |
| US11871901B2 (en) | 2012-05-20 | 2024-01-16 | Cilag Gmbh International | Method for situational awareness for surgical network or surgical network connected device capable of adjusting function based on a sensed situation or usage |
| EA034550B1 (ru) * | 2013-03-09 | 2020-02-19 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способы лечения, снижения частоты и/или профилактики ишемических событий |
| WO2014209389A1 (en) * | 2013-06-26 | 2014-12-31 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US11504192B2 (en) | 2014-10-30 | 2022-11-22 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
| CN115990138A (zh) | 2015-01-14 | 2023-04-21 | 奇斯药制品公司 | 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法 |
| MA49452A (fr) | 2017-06-23 | 2021-05-05 | Chiesi Farm Spa | Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire |
| US11510741B2 (en) | 2017-10-30 | 2022-11-29 | Cilag Gmbh International | Method for producing a surgical instrument comprising a smart electrical system |
| US11911045B2 (en) | 2017-10-30 | 2024-02-27 | Cllag GmbH International | Method for operating a powered articulating multi-clip applier |
| US11311342B2 (en) | 2017-10-30 | 2022-04-26 | Cilag Gmbh International | Method for communicating with surgical instrument systems |
| US11317919B2 (en) | 2017-10-30 | 2022-05-03 | Cilag Gmbh International | Clip applier comprising a clip crimping system |
| US11801098B2 (en) | 2017-10-30 | 2023-10-31 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
| US11564756B2 (en) | 2017-10-30 | 2023-01-31 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
| US11793537B2 (en) | 2017-10-30 | 2023-10-24 | Cilag Gmbh International | Surgical instrument comprising an adaptive electrical system |
| US11026687B2 (en) | 2017-10-30 | 2021-06-08 | Cilag Gmbh International | Clip applier comprising clip advancing systems |
| US11229436B2 (en) | 2017-10-30 | 2022-01-25 | Cilag Gmbh International | Surgical system comprising a surgical tool and a surgical hub |
| US11291510B2 (en) | 2017-10-30 | 2022-04-05 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
| US11969142B2 (en) | 2017-12-28 | 2024-04-30 | Cilag Gmbh International | Method of compressing tissue within a stapling device and simultaneously displaying the location of the tissue within the jaws |
| US11419667B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Ultrasonic energy device which varies pressure applied by clamp arm to provide threshold control pressure at a cut progression location |
| US11045591B2 (en) | 2017-12-28 | 2021-06-29 | Cilag Gmbh International | Dual in-series large and small droplet filters |
| US10695081B2 (en) | 2017-12-28 | 2020-06-30 | Ethicon Llc | Controlling a surgical instrument according to sensed closure parameters |
| US10966791B2 (en) | 2017-12-28 | 2021-04-06 | Ethicon Llc | Cloud-based medical analytics for medical facility segmented individualization of instrument function |
| US11571234B2 (en) | 2017-12-28 | 2023-02-07 | Cilag Gmbh International | Temperature control of ultrasonic end effector and control system therefor |
| US11678881B2 (en) | 2017-12-28 | 2023-06-20 | Cilag Gmbh International | Spatial awareness of surgical hubs in operating rooms |
| US11633237B2 (en) | 2017-12-28 | 2023-04-25 | Cilag Gmbh International | Usage and technique analysis of surgeon / staff performance against a baseline to optimize device utilization and performance for both current and future procedures |
| US10892995B2 (en) | 2017-12-28 | 2021-01-12 | Ethicon Llc | Surgical network determination of prioritization of communication, interaction, or processing based on system or device needs |
| US11056244B2 (en) | 2017-12-28 | 2021-07-06 | Cilag Gmbh International | Automated data scaling, alignment, and organizing based on predefined parameters within surgical networks |
| US11419630B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Surgical system distributed processing |
| US10943454B2 (en) | 2017-12-28 | 2021-03-09 | Ethicon Llc | Detection and escalation of security responses of surgical instruments to increasing severity threats |
| US11109866B2 (en) | 2017-12-28 | 2021-09-07 | Cilag Gmbh International | Method for circular stapler control algorithm adjustment based on situational awareness |
| US10755813B2 (en) | 2017-12-28 | 2020-08-25 | Ethicon Llc | Communication of smoke evacuation system parameters to hub or cloud in smoke evacuation module for interactive surgical platform |
| US11589888B2 (en) | 2017-12-28 | 2023-02-28 | Cilag Gmbh International | Method for controlling smart energy devices |
| US20190201042A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Determining the state of an ultrasonic electromechanical system according to frequency shift |
| US11026751B2 (en) | 2017-12-28 | 2021-06-08 | Cilag Gmbh International | Display of alignment of staple cartridge to prior linear staple line |
| US20190201090A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Capacitive coupled return path pad with separable array elements |
| US11304745B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Surgical evacuation sensing and display |
| US20190206569A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Method of cloud based data analytics for use with the hub |
| US11540855B2 (en) | 2017-12-28 | 2023-01-03 | Cilag Gmbh International | Controlling activation of an ultrasonic surgical instrument according to the presence of tissue |
| US11213359B2 (en) | 2017-12-28 | 2022-01-04 | Cilag Gmbh International | Controllers for robot-assisted surgical platforms |
| US10932872B2 (en) | 2017-12-28 | 2021-03-02 | Ethicon Llc | Cloud-based medical analytics for linking of local usage trends with the resource acquisition behaviors of larger data set |
| US11304763B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Image capturing of the areas outside the abdomen to improve placement and control of a surgical device in use |
| US12062442B2 (en) | 2017-12-28 | 2024-08-13 | Cilag Gmbh International | Method for operating surgical instrument systems |
| US11273001B2 (en) | 2017-12-28 | 2022-03-15 | Cilag Gmbh International | Surgical hub and modular device response adjustment based on situational awareness |
| US11559308B2 (en) | 2017-12-28 | 2023-01-24 | Cilag Gmbh International | Method for smart energy device infrastructure |
| US11304699B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Method for adaptive control schemes for surgical network control and interaction |
| US11786251B2 (en) | 2017-12-28 | 2023-10-17 | Cilag Gmbh International | Method for adaptive control schemes for surgical network control and interaction |
| US11147607B2 (en) | 2017-12-28 | 2021-10-19 | Cilag Gmbh International | Bipolar combination device that automatically adjusts pressure based on energy modality |
| WO2019133143A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Surgical hub and modular device response adjustment based on situational awareness |
| US11013563B2 (en) | 2017-12-28 | 2021-05-25 | Ethicon Llc | Drive arrangements for robot-assisted surgical platforms |
| US10918310B2 (en) | 2018-01-03 | 2021-02-16 | Biosense Webster (Israel) Ltd. | Fast anatomical mapping (FAM) using volume filling |
| US11051876B2 (en) | 2017-12-28 | 2021-07-06 | Cilag Gmbh International | Surgical evacuation flow paths |
| US11832840B2 (en) | 2017-12-28 | 2023-12-05 | Cilag Gmbh International | Surgical instrument having a flexible circuit |
| US11308075B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Surgical network, instrument, and cloud responses based on validation of received dataset and authentication of its source and integrity |
| US11317937B2 (en) | 2018-03-08 | 2022-05-03 | Cilag Gmbh International | Determining the state of an ultrasonic end effector |
| US11278281B2 (en) | 2017-12-28 | 2022-03-22 | Cilag Gmbh International | Interactive surgical system |
| JP2021509061A (ja) | 2017-12-28 | 2021-03-18 | エシコン エルエルシーＥｔｈｉｃｏｎ ＬＬＣ | 状況認識に基づく外科用デバイスの機能の調節 |
| US11832899B2 (en) | 2017-12-28 | 2023-12-05 | Cilag Gmbh International | Surgical systems with autonomously adjustable control programs |
| US11446052B2 (en) | 2017-12-28 | 2022-09-20 | Cilag Gmbh International | Variation of radio frequency and ultrasonic power level in cooperation with varying clamp arm pressure to achieve predefined heat flux or power applied to tissue |
| US11410259B2 (en) | 2017-12-28 | 2022-08-09 | Cilag Gmbh International | Adaptive control program updates for surgical devices |
| US11423007B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Adjustment of device control programs based on stratified contextual data in addition to the data |
| US10892899B2 (en) | 2017-12-28 | 2021-01-12 | Ethicon Llc | Self describing data packets generated at an issuing instrument |
| US10758310B2 (en) | 2017-12-28 | 2020-09-01 | Ethicon Llc | Wireless pairing of a surgical device with another device within a sterile surgical field based on the usage and situational awareness of devices |
| US11234756B2 (en) | 2017-12-28 | 2022-02-01 | Cilag Gmbh International | Powered surgical tool with predefined adjustable control algorithm for controlling end effector parameter |
| US11666331B2 (en) | 2017-12-28 | 2023-06-06 | Cilag Gmbh International | Systems for detecting proximity of surgical end effector to cancerous tissue |
| US11100631B2 (en) | 2017-12-28 | 2021-08-24 | Cilag Gmbh International | Use of laser light and red-green-blue coloration to determine properties of back scattered light |
| US11284936B2 (en) | 2017-12-28 | 2022-03-29 | Cilag Gmbh International | Surgical instrument having a flexible electrode |
| US10849697B2 (en) | 2017-12-28 | 2020-12-01 | Ethicon Llc | Cloud interface for coupled surgical devices |
| US11464535B2 (en) | 2017-12-28 | 2022-10-11 | Cilag Gmbh International | Detection of end effector emersion in liquid |
| US10595887B2 (en) | 2017-12-28 | 2020-03-24 | Ethicon Llc | Systems for adjusting end effector parameters based on perioperative information |
| US11602393B2 (en) | 2017-12-28 | 2023-03-14 | Cilag Gmbh International | Surgical evacuation sensing and generator control |
| US10987178B2 (en) | 2017-12-28 | 2021-04-27 | Ethicon Llc | Surgical hub control arrangements |
| US11744604B2 (en) | 2017-12-28 | 2023-09-05 | Cilag Gmbh International | Surgical instrument with a hardware-only control circuit |
| US12396806B2 (en) | 2017-12-28 | 2025-08-26 | Cilag Gmbh International | Adjustment of a surgical device function based on situational awareness |
| US11076921B2 (en) | 2017-12-28 | 2021-08-03 | Cilag Gmbh International | Adaptive control program updates for surgical hubs |
| US10944728B2 (en) | 2017-12-28 | 2021-03-09 | Ethicon Llc | Interactive surgical systems with encrypted communication capabilities |
| US11160605B2 (en) | 2017-12-28 | 2021-11-02 | Cilag Gmbh International | Surgical evacuation sensing and motor control |
| US11432885B2 (en) | 2017-12-28 | 2022-09-06 | Cilag Gmbh International | Sensing arrangements for robot-assisted surgical platforms |
| US11266468B2 (en) | 2017-12-28 | 2022-03-08 | Cilag Gmbh International | Cooperative utilization of data derived from secondary sources by intelligent surgical hubs |
| US11903601B2 (en) | 2017-12-28 | 2024-02-20 | Cilag Gmbh International | Surgical instrument comprising a plurality of drive systems |
| US11291495B2 (en) | 2017-12-28 | 2022-04-05 | Cilag Gmbh International | Interruption of energy due to inadvertent capacitive coupling |
| US12458351B2 (en) | 2017-12-28 | 2025-11-04 | Cilag Gmbh International | Variable output cartridge sensor assembly |
| US11786245B2 (en) | 2017-12-28 | 2023-10-17 | Cilag Gmbh International | Surgical systems with prioritized data transmission capabilities |
| US11096693B2 (en) | 2017-12-28 | 2021-08-24 | Cilag Gmbh International | Adjustment of staple height of at least one row of staples based on the sensed tissue thickness or force in closing |
| US11364075B2 (en) | 2017-12-28 | 2022-06-21 | Cilag Gmbh International | Radio frequency energy device for delivering combined electrical signals |
| US11389164B2 (en) | 2017-12-28 | 2022-07-19 | Cilag Gmbh International | Method of using reinforced flexible circuits with multiple sensors to optimize performance of radio frequency devices |
| US11771487B2 (en) | 2017-12-28 | 2023-10-03 | Cilag Gmbh International | Mechanisms for controlling different electromechanical systems of an electrosurgical instrument |
| US11132462B2 (en) | 2017-12-28 | 2021-09-28 | Cilag Gmbh International | Data stripping method to interrogate patient records and create anonymized record |
| US11559307B2 (en) | 2017-12-28 | 2023-01-24 | Cilag Gmbh International | Method of robotic hub communication, detection, and control |
| US11896322B2 (en) | 2017-12-28 | 2024-02-13 | Cilag Gmbh International | Sensing the patient position and contact utilizing the mono-polar return pad electrode to provide situational awareness to the hub |
| US11179208B2 (en) | 2017-12-28 | 2021-11-23 | Cilag Gmbh International | Cloud-based medical analytics for security and authentication trends and reactive measures |
| US11311306B2 (en) | 2017-12-28 | 2022-04-26 | Cilag Gmbh International | Surgical systems for detecting end effector tissue distribution irregularities |
| US11529187B2 (en) | 2017-12-28 | 2022-12-20 | Cilag Gmbh International | Surgical evacuation sensor arrangements |
| US12096916B2 (en) | 2017-12-28 | 2024-09-24 | Cilag Gmbh International | Method of sensing particulate from smoke evacuated from a patient, adjusting the pump speed based on the sensed information, and communicating the functional parameters of the system to the hub |
| US11864728B2 (en) | 2017-12-28 | 2024-01-09 | Cilag Gmbh International | Characterization of tissue irregularities through the use of mono-chromatic light refractivity |
| US11937769B2 (en) | 2017-12-28 | 2024-03-26 | Cilag Gmbh International | Method of hub communication, processing, storage and display |
| US11818052B2 (en) | 2017-12-28 | 2023-11-14 | Cilag Gmbh International | Surgical network determination of prioritization of communication, interaction, or processing based on system or device needs |
| US11464559B2 (en) | 2017-12-28 | 2022-10-11 | Cilag Gmbh International | Estimating state of ultrasonic end effector and control system therefor |
| US11969216B2 (en) | 2017-12-28 | 2024-04-30 | Cilag Gmbh International | Surgical network recommendations from real time analysis of procedure variables against a baseline highlighting differences from the optimal solution |
| US11202570B2 (en) | 2017-12-28 | 2021-12-21 | Cilag Gmbh International | Communication hub and storage device for storing parameters and status of a surgical device to be shared with cloud based analytics systems |
| US11576677B2 (en) | 2017-12-28 | 2023-02-14 | Cilag Gmbh International | Method of hub communication, processing, display, and cloud analytics |
| US11612444B2 (en) | 2017-12-28 | 2023-03-28 | Cilag Gmbh International | Adjustment of a surgical device function based on situational awareness |
| US11857152B2 (en) | 2017-12-28 | 2024-01-02 | Cilag Gmbh International | Surgical hub spatial awareness to determine devices in operating theater |
| US11324557B2 (en) | 2017-12-28 | 2022-05-10 | Cilag Gmbh International | Surgical instrument with a sensing array |
| US11424027B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Method for operating surgical instrument systems |
| US11659023B2 (en) | 2017-12-28 | 2023-05-23 | Cilag Gmbh International | Method of hub communication |
| US11069012B2 (en) | 2017-12-28 | 2021-07-20 | Cilag Gmbh International | Interactive surgical systems with condition handling of devices and data capabilities |
| US11896443B2 (en) | 2017-12-28 | 2024-02-13 | Cilag Gmbh International | Control of a surgical system through a surgical barrier |
| US11376002B2 (en) | 2017-12-28 | 2022-07-05 | Cilag Gmbh International | Surgical instrument cartridge sensor assemblies |
| US20190201112A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Computer implemented interactive surgical systems |
| US12127729B2 (en) | 2017-12-28 | 2024-10-29 | Cilag Gmbh International | Method for smoke evacuation for surgical hub |
| US11166772B2 (en) | 2017-12-28 | 2021-11-09 | Cilag Gmbh International | Surgical hub coordination of control and communication of operating room devices |
| US11253315B2 (en) | 2017-12-28 | 2022-02-22 | Cilag Gmbh International | Increasing radio frequency to create pad-less monopolar loop |
| US11257589B2 (en) | 2017-12-28 | 2022-02-22 | Cilag Gmbh International | Real-time analysis of comprehensive cost of all instrumentation used in surgery utilizing data fluidity to track instruments through stocking and in-house processes |
| US11304720B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Activation of energy devices |
| US12376855B2 (en) | 2017-12-28 | 2025-08-05 | Cilag Gmbh International | Safety systems for smart powered surgical stapling |
| US11998193B2 (en) | 2017-12-28 | 2024-06-04 | Cilag Gmbh International | Method for usage of the shroud as an aspect of sensing or controlling a powered surgical device, and a control algorithm to adjust its default operation |
| US11986233B2 (en) | 2018-03-08 | 2024-05-21 | Cilag Gmbh International | Adjustment of complex impedance to compensate for lost power in an articulating ultrasonic device |
| US11464532B2 (en) | 2018-03-08 | 2022-10-11 | Cilag Gmbh International | Methods for estimating and controlling state of ultrasonic end effector |
| US11259830B2 (en) | 2018-03-08 | 2022-03-01 | Cilag Gmbh International | Methods for controlling temperature in ultrasonic device |
| US12303159B2 (en) | 2018-03-08 | 2025-05-20 | Cilag Gmbh International | Methods for estimating and controlling state of ultrasonic end effector |
| US11278280B2 (en) | 2018-03-28 | 2022-03-22 | Cilag Gmbh International | Surgical instrument comprising a jaw closure lockout |
| US11259806B2 (en) | 2018-03-28 | 2022-03-01 | Cilag Gmbh International | Surgical stapling devices with features for blocking advancement of a camming assembly of an incompatible cartridge installed therein |
| US11129611B2 (en) | 2018-03-28 | 2021-09-28 | Cilag Gmbh International | Surgical staplers with arrangements for maintaining a firing member thereof in a locked configuration unless a compatible cartridge has been installed therein |
| US11207067B2 (en) | 2018-03-28 | 2021-12-28 | Cilag Gmbh International | Surgical stapling device with separate rotary driven closure and firing systems and firing member that engages both jaws while firing |
| US10973520B2 (en) | 2018-03-28 | 2021-04-13 | Ethicon Llc | Surgical staple cartridge with firing member driven camming assembly that has an onboard tissue cutting feature |
| US11471156B2 (en) | 2018-03-28 | 2022-10-18 | Cilag Gmbh International | Surgical stapling devices with improved rotary driven closure systems |
| US11096688B2 (en) | 2018-03-28 | 2021-08-24 | Cilag Gmbh International | Rotary driven firing members with different anvil and channel engagement features |
| US11090047B2 (en) | 2018-03-28 | 2021-08-17 | Cilag Gmbh International | Surgical instrument comprising an adaptive control system |
| US11219453B2 (en) | 2018-03-28 | 2022-01-11 | Cilag Gmbh International | Surgical stapling devices with cartridge compatible closure and firing lockout arrangements |
| US11357503B2 (en) | 2019-02-19 | 2022-06-14 | Cilag Gmbh International | Staple cartridge retainers with frangible retention features and methods of using same |
| US11369377B2 (en) | 2019-02-19 | 2022-06-28 | Cilag Gmbh International | Surgical stapling assembly with cartridge based retainer configured to unlock a firing lockout |
| US11464511B2 (en) | 2019-02-19 | 2022-10-11 | Cilag Gmbh International | Surgical staple cartridges with movable authentication key arrangements |
| US11317915B2 (en) | 2019-02-19 | 2022-05-03 | Cilag Gmbh International | Universal cartridge based key feature that unlocks multiple lockout arrangements in different surgical staplers |
| US11259807B2 (en) | 2019-02-19 | 2022-03-01 | Cilag Gmbh International | Staple cartridges with cam surfaces configured to engage primary and secondary portions of a lockout of a surgical stapling device |
| USD964564S1 (en) | 2019-06-25 | 2022-09-20 | Cilag Gmbh International | Surgical staple cartridge retainer with a closure system authentication key |
| USD950728S1 (en) | 2019-06-25 | 2022-05-03 | Cilag Gmbh International | Surgical staple cartridge |
| USD952144S1 (en) | 2019-06-25 | 2022-05-17 | Cilag Gmbh International | Surgical staple cartridge retainer with firing system authentication key |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2530247B1 (fr) * | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| US5256559A (en) | 1988-03-04 | 1993-10-26 | Biogen, Inc. | Methods and compositions for inhibiting platelet aggregation |
| FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| KR100315612B1 (ko) | 1993-02-10 | 2002-06-20 | 추후제출 | N-알킬-2-치환아데노신트리포스페이트동족체 |
| ID21635A (id) | 1996-12-20 | 1999-07-08 | Astra Pharma Prod | Komposisi farmasi untuk pengeringan beku |
| SE9702680D0 (sv) | 1997-07-11 | 1997-07-11 | Astra Pharma Prod | New formulation |
| SE9904377D0 (sv) | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
| AU2001267916B2 (en) * | 2000-07-06 | 2004-09-09 | Daiichi Sankyo Company, Limited | Hydropyridine derivative acid addition salts |
| US7132408B2 (en) * | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| US7790362B2 (en) | 2003-07-08 | 2010-09-07 | Accumetrics, Inc. | Controlled platelet activation to monitor therapy of ADP antagonists |
| US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| US7749981B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| WO2005087266A1 (en) * | 2004-03-05 | 2005-09-22 | Vddi Pharmaceuticals | Combination therapy for inhibition of platelet aggregation |
| US20080214599A1 (en) * | 2005-08-19 | 2008-09-04 | John Thomas Brandt | Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases |
| DE102006020386A1 (de) * | 2006-04-28 | 2007-10-31 | Dade Behring Marburg Gmbh | Verfahren zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen |
| CA2623449C (en) | 2008-03-27 | 2010-11-02 | Lance Baldo | A novel use of bivalirudin in the treatment of acute coronary syndrome |
| WO2009140092A1 (en) | 2008-05-13 | 2009-11-19 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US9427448B2 (en) | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US20120141468A1 (en) | 2008-05-13 | 2012-06-07 | Lisa Ruderman Chen | Maintenance of platelet inhibition during antiplatelet therapy |
| US20130303477A1 (en) | 2008-05-13 | 2013-11-14 | The Medicines Company | Maintenance of Platelet Inhibition During Antiplatelet Therapy |
| US8759316B2 (en) * | 2008-05-13 | 2014-06-24 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US8680052B1 (en) * | 2013-03-09 | 2014-03-25 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| BR112012011298B1 (pt) | 2009-11-11 | 2021-12-14 | Chiesi Farmaceutici S.P.A. | Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| EP2563369A2 (en) | 2010-04-29 | 2013-03-06 | Thrombologic APS | Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof |
-
2009
- 2009-05-04 WO PCT/US2009/042681 patent/WO2009140092A1/en not_active Ceased
- 2009-05-13 EP EP09747490.2A patent/EP2276541B1/en active Active
- 2009-05-13 WO PCT/US2009/043820 patent/WO2009140407A1/en not_active Ceased
- 2009-05-13 HR HRP20161443TT patent/HRP20161443T1/hr unknown
- 2009-05-13 ES ES09747490.2T patent/ES2601524T3/es active Active
- 2009-05-13 CN CN2009801266781A patent/CN102089035A/zh active Pending
- 2009-05-13 AU AU2009246396A patent/AU2009246396B2/en active Active
- 2009-05-13 PT PT97474902T patent/PT2276541T/pt unknown
- 2009-05-13 DK DK09747490.2T patent/DK2276541T3/da active
- 2009-05-13 JP JP2011509659A patent/JP5792059B2/ja active Active
- 2009-05-13 US US12/990,332 patent/US8871736B2/en active Active
- 2009-05-13 HU HUE09747490A patent/HUE031704T2/hu unknown
- 2009-05-13 PL PL09747490T patent/PL2276541T3/pl unknown
- 2009-05-13 CA CA2724470A patent/CA2724470C/en active Active
- 2009-05-13 BR BRPI0912693A patent/BRPI0912693B8/pt active IP Right Grant
- 2009-05-13 LT LTEP09747490.2T patent/LT2276541T/lt unknown
- 2009-05-13 SI SI200931550A patent/SI2276541T1/sl unknown
-
2013
- 2013-12-18 JP JP2013260851A patent/JP2014077005A/ja active Pending
-
2016
- 2016-04-24 US US15/136,979 patent/US10022391B2/en active Active
- 2016-11-03 CY CY20161101124T patent/CY1118653T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009140092A1 (en) | 2009-11-19 |
| WO2009140407A1 (en) | 2009-11-19 |
| SI2276541T1 (sl) | 2017-02-28 |
| AU2009246396A1 (en) | 2009-11-19 |
| CY1118653T1 (el) | 2017-07-12 |
| EP2276541A1 (en) | 2011-01-26 |
| CA2724470A1 (en) | 2009-11-19 |
| US10022391B2 (en) | 2018-07-17 |
| HUE031704T2 (hu) | 2017-07-28 |
| JP2011520899A (ja) | 2011-07-21 |
| JP2014077005A (ja) | 2014-05-01 |
| HRP20161443T1 (hr) | 2016-12-30 |
| BRPI0912693A2 (pt) | 2019-01-15 |
| AU2009246396B2 (en) | 2015-07-09 |
| ES2601524T3 (es) | 2017-02-15 |
| LT2276541T (lt) | 2016-12-12 |
| EP2276541A4 (en) | 2012-05-09 |
| US8871736B2 (en) | 2014-10-28 |
| EP2276541B1 (en) | 2016-08-03 |
| BRPI0912693B8 (pt) | 2021-05-25 |
| US20170049798A1 (en) | 2017-02-23 |
| CN102089035A (zh) | 2011-06-08 |
| PL2276541T3 (pl) | 2017-08-31 |
| BRPI0912693B1 (pt) | 2021-05-11 |
| US20110288043A1 (en) | 2011-11-24 |
| JP5792059B2 (ja) | 2015-10-07 |
| CA2724470C (en) | 2018-01-02 |
| PT2276541T (pt) | 2016-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2276541T3 (da) | Opretholdelse af trombocythæmning under antitrombocytbehandling | |
| US11510934B2 (en) | Maintenance of platelet inhibition during antiplatelet therapy | |
| US9320754B2 (en) | Maintenance of platelet inhibition during antiplatelet therapy | |
| BR112012011298B1 (pt) | Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos | |
| US8759316B2 (en) | Maintenance of platelet inhibition during antiplatelet therapy | |
| WO2014163656A1 (en) | Maintenance of platelet inhibition during antiplatelet therapy | |
| CA3232633A1 (en) | Milvexian for prevention and treatment of thromboembolic disorders | |
| JP6840197B2 (ja) | 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 | |
| Bendel et al. | Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation | |
| WO2014209389A1 (en) | Maintenance of platelet inhibition during antiplatelet therapy |